Amylyx Pharmaceuticals announces AMX0035 demonstrated statistically significant treatment benefit in ALS in CENTAUR trial

This article was originally published here

In the study, participants taking AMX0035 had a statistically significant slowing of ALS disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) compared to placebo (p<0.05),

The post Amylyx Pharmaceuticals announces AMX0035 demonstrated statistically significant treatment benefit in ALS in CENTAUR trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply